From a long-term perspective, $MOH (+0.25%) continues to be an attractive roll-up strategy that can benefit from adding smaller single-state health insurers to its platform. 

Molina's attractive valuation, cost control strategies, and growth outlook make it a potential buy for investors looking for long-term rewards.

$MOH (+0.25%) stock is down nearly -25% from YTD highs, but Q2 results show stabilizing medical expense ratios, assuaging investor fears.

Its attractive valuation, cost control strategies, and growth outlook make it a potential buy for investors looking for long-term upside. Anyone bullish on this stock?🤔

$MOH (+0.25%) I know that maybe this company is little known but I want to tell you to prepare a cup of tea and go and see its balance sheet, it's worth it.

#tech

#stockanalysis